Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)
- 8 December 2022
- journal article
- research article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 58, 152149
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- Bill and Melinda Gates Foundation (INV018455, UL1TR002649)
- American Heart Association
- National Center for Advancing Translational Sciences (U24 TR002306)
- Rheumatology Research Foundation
- National Institutes of Health (K23AI120855)
This publication has 21 references indexed in Scilit:
- Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona RegistryClinical Rheumatology, 2017
- Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future DirectionsGastroenterology, 2017
- Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patientsClinical and Experimental Immunology, 2014
- A drug safety evaluation of rituximab and risk of hepatitis BExpert Opinion on Drug Safety, 2014
- Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing RegimensThe Journal of Immunology, 2011
- Rituximab-Associated InfectionsSeminars in Hematology, 2010
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- B lymphocyte depletion therapy with rituximab in rheumatoid arthritisRheumatic Disease Clinics of North America, 2004
- Bias reduction of maximum likelihood estimatesBiometrika, 1993
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992